ARMP Armata Pharmaceuticals Inc

AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update conference call on Monday, May 15, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call:

    U.S. 877-866-5534 International 346-406-0930 Passcode 20313217   Live Webcast:

AmpliPhi IR Website

The webcast replay will be available approximately 2 hours

after completion of the call and will be archived for 30 days.

  Replay: U.S. 855-859-2056 International 404-537-3406 Passcode 20313217

The replay will be available for 48 hours starting approximately

2 hours after completion of the call.

 

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170511005278/en/

At the Company:AmpliPhi BiosciencesMatthew Dansey, (858) 800-4869md@ampliphibio.comorInvestor Relations:LHAJody Cain, (310) 691-7100jcain@lhai.com